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Objectives: Atypical antipsychotics (AAPs) carry a significant risk of cardiometabolic 
side effects, including insulin resistance. It is thought that the insulin resistance 
resulting from the use of AAPs may be associated with changes in DNA methylation. 
We aimed to identify and validate a candidate gene associated with AAP- induced 
insulin resistance by using a multi- step approach that included an epigenome- wide 
association study (EWAS) and validation with site- specific methylation and metabo-
lomics data.
Methods: Subjects with bipolar disorder treated with AAPs or lithium monotherapy 
were recruited for a cross- sectional visit to analyze peripheral blood DNA methylation 
and insulin resistance. Epigenome- wide DNA methylation was analyzed in a discovery 
sample (n = 48) using the Illumina 450K BeadChip. Validation analyses of the 
epigenome- wide findings occurred in a separate sample (n = 72) using site- specific 
methylation with pyrosequencing and untargeted metabolomics data. Regression 
analyses were conducted controlling for known confounders in all analyses and a 
mediation analysis was performed to investigate if AAP- induced insulin resistance 
occurs through changes in DNA methylation.
Results: A differentially methylated probe associated with insulin resistance was 
 discovered and validated in the fatty acyl CoA reductase 2 (FAR2) gene of chromo-
some 12. Functional associations of this DNA methylation site with untargeted 
phospholipid- related metabolites were also detected. Our results identified a mediat-
ing effect of this FAR2 methylation site on AAP- induced insulin resistance.
Conclusions: Going forward, prospective, longitudinal studies assessing comprehen-
sive changes in FAR2 DNA methylation, expression, and lipid metabolism before and 
after AAP treatment are required to assess its potential role in the development of 
insulin resistance.
K E Y W O R D S
antipsychotics, bipolar disorder, insulin, mediation, methylation
1Department of Pharmacy Practice, Wayne 
State University, Eugene Applebaum College 
of Pharmacy and Health Sciences, Detroit, 
MI, USA
2Department of Environmental Health 
Sciences, University of Michigan School of 
Public Health, Ann Arbor, MI, USA
3Department of Clinical, Social, and 
Administrative Sciences, University of 
Michigan, College of Pharmacy, Ann Arbor, 
MI, USA
4Department of Psychiatry, University of 
Michigan, School of Medicine, Ann Arbor, 
MI, USA
Correspondence
Kyle J. Burghardt, Department of Pharmacy 
Practice, Eugene Applebaum College of 
Pharmacy and Health Sciences, Wayne State 
University, Detroit, MI, USA.
Email: kburg@wayne.edu
O R I G I N A L  A R T I C L E
Gene- specific DNA methylation may mediate atypical 
antipsychotic- induced insulin resistance
Kyle J Burghardt1 | Jacyln M Goodrich2 | Dana C Dolinoy2 | Vicki L Ellingrod3,4
It is estimated that approximately 1–2% of the USA’s population has 
bipolar disorder.1 Psychopharmacologic treatment of bipolar disorder 
utilizes several different medication classes, including mood stabiliz-
ers, antidepressants and benzodiazepines. The atypical antipsychotics 
(AAPs) have become an important maintenance pharmacotherapeutic 
option in the past 10 years.2 Although the efficacy of AAPs in bipolar 
disorder has been shown in randomized, placebo- controlled trials, 
they also carry a significant risk of weight gain, diabetes, metabolic 
syndrome, and cardiovascular disease.3 This may be particularly con-
cerning in severe mental illnesses, like bipolar disorder, which have 
elevated rates of metabolic comorbidity, and, in particular, insulin 
resistance prior to AAP treatment.4,5 Physical health may be linked 
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to psychiatric health. Within bipolar disorder, patients with endocrine 
abnormalities, in particular insulin resistance, have worse psychiatric 
outcomes.6–9 The impact of AAP cardiometabolic side effects on long- 
term psychiatric outcomes is not known; however, given the connec-
tion between cardiometabolic and psychiatric health, as well as the 
high rates of cardiovascular mortality in bipolar disorder, it is important 
to understand how these side effects occur.10 Thus, there is a need 
to identify the mechanisms by which AAPs increase the risk of insu-
lin resistance so that the beneficial effects of these medications can 
be used to treat psychiatric symptoms without sacrificing a patient’s 
physical health or compounding the problem of metabolic illness with-
in this vulnerable population.
Pharmacoepigenetics may aid in understanding the complex 
mechanisms of AAP- induced side effects by examining the interface 
of medication use and gene expression. Previous work has identi-
fied associations between one- carbon metabolism and AAP- induced 
insulin resistance and metabolic syndrome in bipolar disorder as well 
as psychopharmacology- specific effects on the epigenome.11–13 It 
may be plausible that an epigenetic mechanism underlies these side 
effects, since the endpoint of one- carbon metabolism is the produc-
tion of methyl donors that are used for various methylation reactions 
in the body, including DNA methylation. This hypothesis was sup-
ported by identified associations between a global measure of DNA 
methylation and AAP- induced insulin resistance within bipolar disor-
der.14 In the only candidate gene study to date, Moons and colleagues 
found no associations between AAP- induced metabolic side effects 
and genetic or epigenetic variability in the insulin- like growth factor 
2 (IGF2) gene.15
The metabolome, which represents all of the small molecules in 
the cell that arise as a consequence of metabolism, is directed by 
upstream processes including genetic and epigenetic variability. 
Although it can be relatively stable, AAPs may have significant effects 
on the metabolome.16–19 Metabolomics can be a useful tool in study-
ing AAP- induced side effects due to its ability to represent the echo of 
complex lifestyles of individuals interacting with genetic and environ-
mental factors such as medications.20 The changes in the metabolome 
secondary to AAP- induced insulin resistance may be the functional 
consequence of epigenetic changes, and therefore combining these 
two molecular approaches may aid in understanding the pathways 
involved in AAP- induced insulin resistance.21,22
Despite previous work implicating DNA methylation changes in 
AAP- induced insulin resistance at the global level, it is not known 
which regions or genes may be differentially methylated in AAP- 
induced insulin resistance and whether it is a potential mediator of 
the drug- induced side effect. Within this study, we aimed to identify 
differentially methylated genes associated with AAP- induced insulin 
resistance in a multi- step, systematic approach (Fig. S1). In the first 
step, we employed an epigenome- wide association study (EWAS) to 
discover a candidate gene (or genes). In the next steps, we validated 
the discovery finding using site- specific and metabolomics analyses 
in a separate sample. Finally, within the validation analyses, we test-
ed the hypothesis that AAP- induced insulin resistance is mediated by 
our candidate gene’s DNA methylation. Although completion of the 
multi- step design was not guaranteed, we detail below our successful 
identification of a novel candidate gene whose differential methyla-
tion may mediate AAP- induced insulin resistance.
1  | METHODS
1.1 | Subject recruitment
Samples and data for both the discovery and validation samples came 
from an ongoing study on the rates of metabolic syndrome in bipo-
lar disorder and schizophrenia.11 Subjects were included if they had 
a Diagnostic and Statistical Manual of Mental Disorders, 4th edi-
tion, text revision (DSM- IV- TR) diagnosis of bipolar I disorder via the 
structured clinical interview for DSM diagnoses (SCID) and currently 
had been treated with an AAP or lithium monotherapy for at least 
3 months.23 Subjects were excluded if they had a documented meta-
bolic disturbance (e.g., obesity, diabetes or cardiovascular disease) pri-
or to starting their AAP or lithium therapy, were currently treated with 
medications for diabetes, or had an active substance abuse diagnosis 
(smoking was allowed). Subjects underwent a medical and medica-
tion history, and anthropometric, vital sign, psychiatric symptom, and 
insulin resistance [homeostatic model assessment of insulin resistance 
(HOMA- IR)] measurements.24 A fasting (8–10 h) blood draw within 
3 h of the subject’s normal time of awakening was obtained for epige-
netic and metabolomics assessment. Current smoking was defined as 
smoking five or more cigarettes per day. For the purposes of descrip-
tion, AAP use was stratified based on a general metabolic side effect 
risk profile to include the following groups: Group 1 included olanzap-
ine and clozapine, which have the highest propensity to cause meta-
bolic side effects, Group 2 included quetiapine and risperidone, which 
carry a moderate risk of metabolic side effects, and Group 3 included 
aripiprazole and ziprasidone, which are considered to have the lowest 
risk of all AAPs of causing metabolic side effects. Such categorization 
(e.g., low, intermediate and high risk) has been used in previous stud-
ies and is supported by meta- analyses and consensus expert opin-
ion.25–29 All subjects provided informed consent before participating 
and the study was approved by the University of Michigan Medical 
Institutional Review Board (UM- MED IRB).
1.2 | Discovery using an EWAS
From the above cohort, 48 subjects currently treated with AAPs were 
randomly chosen for the discovery step. Genomic DNA was obtained 
from whole blood, bisulfite converted, and submitted to the University 
of Michigan DNA sequencing core for analysis using the Illumina 
Human Methylation 450K BeadChip (San Diego, CA, USA).30 The core 
returned raw image (IDAT) files for analysis by the investigators.
1.3 | Validation: site- specific epigenetic analysis
Validation of the top gene- related finding from the EWAS (detailed 
in the Results) occurred in the validation sample using site- specific 
methylation with pyrosequencing. The validation sample (n = 72 on 
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AAP and lithium monotherapy) was chosen from the same pool of 
samples described in the recruiting process above; however, there was 
no overlap. Primers were created to measure the methylation of the 
Chr12:29302232 site (GR37/HG19) identified from the EWAS using 
the Qiagen Assay Design 2.0 software (Germantown, MD, USA) (Table 
S1). Duplicate reactions were run on a Qiagen Pyrosequencer MD9631 
and duplicates resulting in a coefficient of variation > 2% methylation 
difference were discarded. Two samples were removed from validation 
analysis due to unreliable methylation results. Percent methylation at 
Chr12:29302232 was standardized using a six- point standard curve.32
1.4 | Validation: metabolomics analysis
An untargeted metabolomics analysis in the validation sample was 
conducted using the Michigan Regional Comprehensive Metabolomics 
Resource Core (MRC)2 at the University of Michigan, as described 
elsewhere.33 The core processed all samples and resulting features 
were stored and further processed using in- house developed software 
and finally returned as a single, normalized (via internal standards), 
and pre- processed (auto- scaled, log- transformed) data set. The core 
assisted in narrowing the returned data set to metabolites related to 
our discovery gene findings using their in- house pathway software as 
well as commercially available platforms. Metabolites were chosen if 
they were found in phospholipid pathways (this pathway was chosen 
based on the discovery EWAS finding) by entering metabolite iden-
tifiers into Kegg Reaction, Metaboanalyst and Metscape Databases.
1.5 | Statistical analysis
Demographic and clinical characteristics are described using means 
with standard deviation or percentages. The discovery and validation 
samples were compared using Student t- tests for continuous variables 
and chi- square or Fisher’s exact tests for categorical data. Raw IDAT 
data files from the Illumina 450K BeadChip were downloaded from the 
DNA sequencing core and processed using available bioinformatics 
pipelines in R Statistical software 3.1.34,35 These pipelines included 
the CHAMP, Minfi and COMBAT R packages.36–39 No samples were 
removed due to missing data points. Cellular composition was inferred 
by the method of Houseman and colleagues using the FlowSorted.
Blood.450k R package in order to be included as a covariate in the 
analysis, as it has been shown that cellular heterogeneity can be an 
important confounder in EWAS and particularly in studying medica-
tion effects in bipolar patients taking medications.12,40,41 To assess the 
relationship between HOMA- IR and 450K methylation, differentially 
methylated probes were identified using a linear model (‘lm’ in Limma 
package) with the covariates of age, race, gender, AAP group, smoking, 
folate, body mass index (BMI), and cellular composition.42 Covariates 
of age, race, gender, BMI, folate, and smoking were chosen based on 
our previous work and from work showing that they may be consid-
ered biologically relevant predictors of methylation status in addition 
to HOMA- IR.14,43 Furthermore, individual antipsychotics have differ-
ent propensities to cause insulin resistance, and therefore the three 
AAP groups listed above were also included in the model. The use of 
linear modeling with Limma and its benefits in analyzing microarray 
data have been described elsewhere 44 and our modeling improved 
the overall fit (see QQ plot in Fig. S2). Correction for multiple testing 
was performed using the Bonferroni method with an epigenome- wide 
significance level of P < 1.1 × 10−7 (0.05/450 000 sites).
For the validation analyses, the correlation between CpG methyla-
tion (at the site identified from the EWAS) and HOMA- IR was analyzed 
in the validation sample using linear regression.32 Covariates for linear 
regressions were chosen based on the literature, previous results (as 
described above), and the 10% rule to keep covariates that change the 
association between independent and dependent variables of inter-
est by more than 10% when removed. Cellular composition data were 
not available for the validation sample and thus could not be included 
as a covariate. A P- value of < .05 was considered significant for the 
site- specific validation analyses. All genomic coordinates in this study 
are described using the Human Genome Version 19 (HG19) (http://
genome.uesc.ed).
Metabolite data were analyzed by linear regression to assess their 
association with Chr12:29302232 methylation. Dependent variables 
were the relative metabolite levels. Covariates were chosen in the 
same manner as described above for the site- specific analyses. A total 
of 13 metabolites were analyzed, and a false discovery rate (using the 
online tool from http://users.ox.ac.uk/∼npike/fdr/) corrected P- value 
of < .05 was considered statistically significant.
Finally, to test the hypothesis that AAP- induced insulin resistance 
may be explained by medication- induced changes in the candidate 
gene’s methylation, we conducted a mediation analysis. We first ana-
lyzed the association of AAP use with our candidate gene’s methylation 
by evaluating the effect of medication (AAP or lithium monotherapy; 
Fig. S1, Step 4). If this association was significant, we then conducted 
a mediation analysis according to the method of Ditlevsen and col-
leagues.45 An overview of the mediation analysis is provided in Fig. S3.
2  | RESULTS
2.1 | Population characteristics
Forty- eight subjects with bipolar I disorder currently treated with an 
AAP were included in the discovery cohort. A total of 72 subjects 
with bipolar I disorder treated with AAPs (n = 54, 75%) and lithium 
monotherapy (n = 18, 25%) were included in the validation analyses 
(Table 1). The sets were comparable in terms of demographic and 
clinical variables and did not significantly differ based on age, race, 
HOMA- IR or medication use (all P > .07). The validation sample did 
have a higher percentage of female participants (P = .08), African 
American participants (P = .22), and a higher BMI (P = .09).
2.2 | Discovery sample EWAS
After correction for multiple testing, only the top two hits, cg25329211 
and cg10171063, remained significant from the EWAS analysis based 
on HOMA- IR. Probe cg25329211 is located in an intergenic shelf 
region on chromosome 2 and probe cg10171063 is located within a 
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gene called fatty acyl CoA reductase 2 (FAR2) on chromosome 12 at 
position 29302232 (herein referred to as Chr12:29302232 methyla-
tion). The FAR2 enzyme catalyzes the rate- limiting reduction of fatty 
acyl CoAs to fatty alcohols.46 The top 10 differentially methylated 
probes from the EWAS analysis are given in Table 2. A Manhattan 
plot for the EWAS analysis can be found in Figure 1. Although not 
significant after Bonferroni correction, three additional probes within 
the same CpG island (chr12:29302035−29302954) of FAR2 were in 
the top 10 most significant sites associated with HOMA- IR.
2.3 | Validation sample: replication of FAR2 
methylation association with insulin resistance
Due to the enrichment of the FAR2 gene in the top EWAS results, and 
because probe cg10171063 was the only statistically significant hit 
located in a gene coding region, we aimed to replicate the association 
of decreased methylation or hypomethylation at Chr12:29302232 
(cg10171063) with increased HOMA- IR (indicating an insulin- 
resistant state) in an additional sample of subjects with bipolar dis-
order assessed for insulin resistance and currently treated with AAPs 
or lithium monotherapy. The average detected methylation in the 
validation sample at this site was 58.3 ± 16.1 (mean  ± standard devia-
tion) and the association of decreased Chr12:29302232 methylation 
and increased HOMA- IR was replicated (crude beta = −0.08, crude 
P = .0016, adjusted beta = −0.06, adjusted P = .007) while adjusting 
for age, race, gender, BMI, and smoking status (Table 3). Use of the 
same model, while stratifying the validation sample based on medi-
cation use (AAP or lithium monotherapy), only showed this negative 
association between Chr12:29302232 methylation and HOMA- IR in 
AAP- treated subjects (crude beta = −0.09, crude P = .0047, adjusted 
beta = −0.07, adjusted P = .018), while no association was observed 
in subjects treated with lithium (crude beta = −0.005, crude P = .9, 
adjusted beta = −0.008, adjusted P = .8). Although not done in our 
primary validation analyses due to a limited sample size, stratifying 
the sample by AAP metabolic risk (i.e., low, medium and high) showed 
that within all three groups the same negative correlation between 
Chr12:29302232 methylation and HOMA- IR was observed. The 
relationship between Chr12:29302232 hypomethylation and higher 
HOMA- IR in the olanzapine and clozapine group (high metabolic risk) 
did not reach statistical significance (beta = −0.11, P = .06) which may 
be due to the small sample size in this group. The medium- risk group 
TABLE  1 Demographic and clinical characteristics of discovery 
and validation samples
Discovery  
sample (n = 48)
Validation 
sample (n = 72)
Age, years, mean ± SD 45.1 ± 11.2 42.3 ± 12.1
% female 54 69.4
Race/ethnicity, % Caucasian;  
% African American
94; 4 80; 11
BMI, kg/m2, mean ± SD 29.7 ± 6.29 32.3 ± 9.19
HOMA- IR, mean ± SD 6.53 ± 4.92 5.24 ± 2.96
% smoker 27 32
Folate, ng/ml, mean ± SD 18.9 ± 5.98 18.7 ± 6.00
% Group 1 antipsychotic 16 11
% Group 2 antipsychotic 65 40
% Group 3 antipsychotic 19 24
% lithium monotherapy – 25
No significant differences were identified between the discovery and vali-
dation cohorts. Race/ethnicity is categorized as ‘Caucasian’, ‘African 
American’, and ‘Other’. Atypical antipsychotic use was stratified by meta-
bolic risk profile. Group 1 antipsychotics included olanzapine and clozapine, 
which have the highest risk to cause metabolic side effects. Group 2 antip-
sychotics included quetiapine and risperidone, which carry a moderate risk, 
and Group 3 antipsychotics included aripiprazole and ziprasidone, which 
have the lowest risk to cause metabolic side effects. SD = standard devia-
tion; BMI = body mass index; HOMA- IR = homeostatic model assessment 
of insulin resistance.
TABLE  2 Top 10 differentially methylated probes from EWAS analysis based on HOMA- IR
CpG probe Chromosome Gene Base pair Feature
Log2 fold 
change Original P- value
Bonferroni 
corrected P- value
cg25329211 2 NA 64375257 IGR–Shelf −0.004 4.56E- 08 .01
cg10171063 12 FAR2 29302232 Exon 1–Island −0.005 6.98E- 08 .02
cg12503835 8 TSNARE1 143324660 Body–Open Sea −0.02 1.69E- 07 .06
cg04488853 11 CCKBR 6293288 3′ UTR–Shore −0.02 2.49E- 07 .08
cg10902825 12 FAR2 29302179 Exon 1–Island −0.005 2.57E- 07 .09
cg11390073 12 FAR2 29302515 Intron 1– Island −0.009 3.00E- 07 .10
cg24677744 12 FAR2 29302016 Exon 1–Island −0.008 3.01E- 07 .10
cg20697767 17 RPRML 45056325 Exon 1–Island 0.02 3.41E- 07 .12
cg21725878 12 NA 132956918 IGR–Island −0.01 3.86E- 07 .13
cg15076218 1 PIK3R3 46599002 TSS1500–Island 0.01 4.02E- 07 .14
The table lists the top 10 differentially methylated probes (CpG probes) from the epigenome- wide association study (EWAS) analysis based on homeostatic 
model assessment of insulin resistance (HOMA- IR) while adjusting for age, race, gender, atypical antipsychotics group, smoking, folate, body mass index, 
and cellular composition. Location, gene (if applicable), feature of probe and log2 fold change are listed along with original and Bonferroni adjusted P- values. 
The top two hits remained significant after multiple testing correction.
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and low- risk group still had significant negative correlations between 
Chr12:29302232 methylation and HOMA- IR (beta = −0.09, P = .047; 
and beta = −0.07, P = .014, respectively).
2.4 | Validation sample: metabolomics analyses for 
functional effects of FAR2 methylation
Our top gene- related finding from the EWAS analysis identified 
differential methylation of a lipid enzyme gene associated with 
HOMA- IR (FAR2). We restricted our metabolomics analyses in the 
validation sample to identified metabolites related to pathways that 
could be associated with FAR2 in order to reduce Type I error. A 
total of 13 metabolites related to these pathways were identified 
from the known subset of metabolites. These metabolites, as well 
as crude and adjusted beta values and the P- values, for the regres-
sions with Chr12:29302232 methylation are listed in Table 3. The 
levels of linoleoylglycerophosphoethanolamine, palmitoleoylglyc-
erophosphocholine and palmitoylsphingomyelin were negatively 
correlated to Chr12:29302232 methylation, meaning that hyper-
methylation at this site was associated with lower metabolite levels.
F IGURE  1 A Manhattan plot of the 
P- values based on homeostatic model 
assessment of insulin resistance (HOMA- 
IR) while adjusting for age, race, gender, 
antipsychotic type, smoking, folate, body 
mass index (BMI) and cellular composition. 
The x- axis is broken down by chromosome 
and the y- axis is the –log10 P- value. The 
two probes that met the epigenome- wide 
association study (EWAS) significance level 
(upper horizontal line) were in chromosome 
2 (probe cg25329211) and chromosome 12 
(probe cg10171063). The lower horizontal 
line is the suggestive EWAS significance 
threshold cutoff. Note the two hits above 
the significance threshold of 1.1 × 10−7 in 
chromosomes 2 and 12 correspond to the 









HOMA- IR −0.08 .0016* −0.06 .0070*
Arachidonoylglycerophosphoethanolamine 15762.91 .36 11314.09 .57
Hexadecanedioate 0.0069 .47 0.0017 .86
Linoleoylglycerophosphoethanolamine −248848.80 .045* −393919.30 .033*
Octadecanedioate 0.016 .0395* 0.010 .21
Oleoylglycerophosphoethanolamine 19886.00 .76 −2079.11 .98
Palmitoleic acid 0.0031 .42 0.004 .41
Palmitoleoylglycerophosphocholine −0.018 .047* −0.020 .049*
Palmitoyl sphingomyelin −0.015 .035* −0.018 .028*
Palmitoylcarnitine 0.0018 .84 0.0033 .74
Palmitoylplasmenylethanolamine 0.004 .41 0.003 .62
Palmitoylglycerophosphoinositol −0.0013 .88 −0.0066 .50
Stearoylglycerophosphocholine −0.0036 .57 −0.0021 .82
Stearoylglycerophosphoethanolamine −0.0040 .62 −0.0089 .34
Validation analyses investigated associations between CHR12:29302232 methylation and insulin resistance as measured by homeostatic model assessment 
of insulin resistance (HOMA- IR) and were adjusted for age, race, gender, body mass index (BMI), and smoking status. Additional functional analyses investi-
gated associations between Chr12:29302232 and an untargeted metabolomics set related to phospholipid metabolites, adjusting for age, race, gender, BMI 
and folate levels. The units of each metabolite are relative arbitrary units established by the metabolomics core processing methods. Presented P- values for 
the functional metabolite analyses were corrected for multiple testing using the false discovery rate method (a total of 13 metabolites/tests).
*P < .05.
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2.5 | Validation sample: testing of AAP effects on 
FAR2 methylation and HOMA- IR
In the next step of our approach (Fig. S1), we investigated the effect 
of AAP use on FAR2 methylation and HOMA- IR. A linear regression 
adjusting for age, race, and gender confirmed the association between 
AAP use and FAR2 methylation (crude beta = −5.27, P = .037, adjusted 
beta = −5.28, adjusted P = .040). Our data also confirmed the well- 
studied and known effect of AAP use on insulin resistance. A regres-
sion adjusting for age, gender, race, BMI and smoking identified a 
significant association between AAP use and HOMA- IR (crude beta = 
0.922, P = .022, adjusted beta = 0.751, adjusted P = .028).
2.6 | Validation sample: mediation analyses
A mediation analysis aids in understanding to what degree, if any, 
FAR2 methylation may be the mediating factor between AAP use 
and HOMA- IR. The coefficients from sequential modeling described 
above indicated that there were significant associations between (i) 
AAP use and HOMA- IR, (ii) AAP use and FAR2 DNA methylation, and 
(iii) FAR2 methylation and HOMA- IR. The association between AAP 
use and HOMA- IR was not significant when accounting for FAR2 
DNA methylation, suggesting a complete mediation effect by FAR2 
methylation. Calculations using the crude beta coefficients from these 
consecutive regressions (see Fig. S3) estimated a percent mediation of 
40%, indicating that 2/5 of the risk of AAP- induced insulin resistance 
may be mediated by hypomethylation at the FAR2 gene. Thus, the 
direct mediation effect is 60%.
3  | DISCUSSION
To our knowledge, this is the first study to use an epigenome- wide 
platform to investigate epigenetic associations with an AAP- induced 
metabolic side effect. Two differentially methylated probes were iden-
tified in the discovery set, one of which was found within a gene with 
possible biological relevance (i.e., lipid metabolism) to insulin resist-
ance. This methylation site, within the FAR2 gene on chromosome 12 
at position 29302232, was successfully replicated in a separate, vali-
dation sample using site- specific methylation analyses and found to be 
a mediator of the association between AAP use and insulin resistance.
3.1 | Findings from EWAS and methylation validation
The top hit, probe cg25329211 (Chr2: 64375257), is located within 
an intergenic shelf region. The significance of such methylation sites 
is not fully known. However, these locations may be important for 
regulating alternative promoters, preventing unneeded expression 
from intergenic regions, and for splicing events.47,48 Further work is 
needed to investigate the relevance of this finding and its relationship 
to AAP- induced insulin resistance, if any. It may be possible that this 
site could serve as a biomarker regarding the risk for AAP- induced 
insulin resistance despite its current unknown functional significance.
The second CpG site from the EWAS that remained significant 
after correction for multiple testing was located at Chr12:29302232 
(cg10171063). Given the association of this site with a gene, we chose 
to focus our validation work here. We were able to confirm the asso-
ciation of hyopmethylation at this CpG site with insulin resistance as 
measured by HOMA- IR in our validation sample. The methylation site 
of Chr12:29302232 is found within a CpG Island of exon 1 of the FAR2 
gene (also known as the male sterility domain- containing protein 1 
[MLSTD1] gene) within 150 bp of a transcription start site. This gene 
encodes a peroxisomal protein that utilizes fatty acyl CoA substrates 
for conversion to fatty alcohols.46 The production of fatty alcohols is 
the rate- limiting step to the downstream formation of wax monoesters 
and ether phospholipids. Ether phospholipids include both an ether 
bond to an alkyl moiety and an ester bond to a fatty acid, and are 
thought to be important constituents of cell membranes and possi-
bly cell signaling.49 One of the most common classes of ether lipids is 
called plasmalogens, which contain a phospholipid with a glycerol chain 
attachment.50,51 Plasmalogens are found within many human tissues, 
with particularly high concentrations in the central nervous system and 
cardiovascular system, accounting for 15−20% of total phospholipid 
content in cell membranes.50,52 Plasmalogens may have an important 
role in the cardiometabolic health of certain populations.53,54
3.2 | Phospholipid changes and AAP use
Changes in phospholipids including the plasmalogens have been iden-
tified following AAP treatment in several metabolomics studies in 
schizophrenic subjects.16–19,33 In two lipidomic studies, by Kaddurah- 
Doak and McEvoy and colleagues, significant elevations in phospho-
lipid levels were found following AAP treatment in several different 
populations of schizophrenic patients including first episode, treat-
ment naïve, and recurrent episode patients compared to controls. 
Within both studies, increases in a phospholipid, phosphatidyletha-
nolamine, were identified after treatment with AAPs. Xuan and col-
leagues found that myo- inositol, which is required for the synthesis 
of membrane inositol phospholipids, was a statistically significant 
metabolite that defined AAP treatment response in their untargeted 
metabolomics study of risperidone effects in schizophrenic subjects. 
Finally, Oresic and colleagues55 conducted a lipidomic investigation in 
twin pairs discordant for schizophrenia (74% of twins with schizophre-
nia were taking an AAP) and found varying levels of lipids depending 
on the subspecies being analyzed. With their study, they specifically 
identified increases in sphingomyelins in schizophrenic subjects, which 
may support our finding of an association between palmitoylsphin-
gomyelin and Chr12:29302232 methylation. Finally, although the 
difference was not statistically significant in their study, Oresic identi-
fied higher levels of ether phospholipids, which are directly controlled 
by the activity of our FAR2 candidate gene, in schizophrenic subjects 
compared to their discordant twins and healthy controls.
Within our study, insulin resistance was associated with hypometh-
ylation of FAR2. Our study identified possible functional effects of 
Chr12:29302232 methylation using an untargeted metabolomics 
analysis of phospholipid- related metabolites. We identified an inverse 
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relationship between Chr12:29302232 methylation and three metab-
olites, linoleoylglycerophosphoethanolamine, palmitoleoylglycero-
phosphocholine and palmitoylsphingomyelin, where hyopmethylation 
was associated with higher metabolite levels. This relationship may 
follow the general notion that decreased methylation of a gene results 
in increased expression of downstream product associated with that 
gene or vice versa. It may further suggest that methylation in this par-
ticular CpG island of FAR2 may be important for FAR2 gene regulation. 
It may also be plausible that differences in methylation of rate- limiting 
enzymes like that of FAR2 could have substantial effects on the lipid 
balances occurring in the body.
The plasmalogen phospholipids have been characterized as poly-
unsaturated fatty acid (PUFA) ‘sinks’ due to their higher likelihood of 
having linkage to both the n- 3 and n- 6 PUFAs compared to the dia-
cyl alternative.56 Our metabolites included two phospholipids with 
PUFA attachments (arachidonoylglycerophosphoethanolamine and 
linoleoylglycerophosphoethanolamine). Higher relative linoleoylglycero-
phosphoethanolamine levels were found to be significantly associated 
with lower Chr12:29302232 methylation. The intersection of PUFA 
and phospholipid metabolism continues to be a theme in the literature 
regarding both positive and negative AAP outcomes in bipolar disorder 
and schizophrenia 16,18,19,55,57 and further exploration may be warranted.
3.3 | DNA methylation as a mediator of AAP use and 
insulin resistance
Finally, our work showed a mediating effect by DNA methylation at 
FAR2 on AAP- induced insulin resistance. This may give preliminary 
and partial support to our overall hypothesis that AAPs cause changes 
in DNA methylation at particular locations in the genome which sub-
sequently alter RNA, protein and metabolite regulation to cause insu-
lin resistance. We speculate that the lowering of FAR2 methylation 
by AAPs leads to increased production of certain lipid species, lead-
ing to a lipid imbalance and increased insulin resistance. Lipid imbal-
ances have been implicated in insulin resistance pathophysiology.58 
Ultimately, the molecular cause of AAP- induced insulin resistance is 
likely multifactorial and may include several different pathways. It 
could also be highly dependent on the particular population being 
studied. Indeed, genetic variation of lipid- metabolizing enzymes from 
other pathways has been linked to AAP- induced insulin resistance.59 
Our work and that of others has suggested that AAPs may have sig-
nificant effects on the epigenome which could have implications for 
both therapeutic and adverse effects.
3.4 | Strengths and limitations
The findings from this study should be interpreted cautiously in light 
of two main limitations, namely (i) a limited sample size and (ii) lack 
of longitudinal sampling. Psychiatric polypharmacy is well known in 
bipolar disorder and, although we were able to overcome this in our 
sample, it did limit the sample size, which reduces power when correct-
ing for multiple comparisons. Previous work has identified an optimal 
sample size of at least 112 cases and controls to achieve 80% power in 
detecting methylation differences in epigenome- wide studies.60 The 
current study did not reach this suggested sample size and it did not 
include controls and thus could have insufficient power to detect true 
findings. Additionally, the lack of longitudinal samples does not allow 
us to infer causal changes but only single time- point methylation and 
metabolite associations in a population already on AAPs or lithium for 
at least 3 months. Such a study design carries treatment length and 
dosage variability that should be taken into account when interpreting 
the results. Thus, replication in longitudinal formats and other AAP- 
treated populations should be pursued to investigate the validity of 
our identified gene as well as other top hits from our study and/or 
other candidate pathways involved in AAP- induced insulin resistance.
A few other limitations should be considered. We did not have the 
ability to assess changes in FAR2 gene expression (with RNA) in relation 
to AAP- induced insulin resistance as RNA was not available. We also 
only validated a single DNA methylation site and studies in the future 
should expand the methylation analyses to include other areas of the 
FAR2 gene. Our metabolite data only measured relative levels, and so 
the lipidomic pathways that may be influenced by this gene’s methyla-
tion require further, targeted exploration. Finally, our work also includ-
ed both obese and nonobese subjects. BMI is a well- known risk factor 
of insulin resistance and this was seen in our study samples (data not 
shown). Nevertheless, when analyses were adjusted for BMI, our find-
ings were still significant. Additionally, we describe the effects of obesity 
on Chr12:29302232 methylation and metabolite levels in Table S2 for 
descriptive purposes; however, detected effects were minimal. Obesity 
remains a significant independent predictor of insulin resistance and so 
future studies will need to separate the effects of AAP- induced obesity 
and insulin resistance on gene methylation and metabolite changes with 
either prospective studies or studies in nonobese populations.
This study had several strengths, including an epigenome- wide 
analysis coupled with validation analyses that utilized site- specific 
methylation and metabolomics data in two samples of subjects with 
bipolar disorder with well- characterized medication regimens. Within 
the top ten differentially methylated genes associated with HOMA- IR 
from our EWAS analysis, four were found within the same CpG island 
of the FAR2 gene and all were found to have lower methylation with 
higher HOMA- IR. This should be interpreted cautiously as only the top 
two genes from this list remained significant after multiple testing cor-
rections, but our unbiased discovery approach followed by validation 
does strengthen this candidate gene finding. Although the sample size 
was limited and cross- sectional, the ability to replicate our finding and 
the possible biological relevance of the FAR2 gene do strengthen the 
findings in their present form. We cannot rule out a reverse causation 
effect on our identified gene methylation, meaning that insulin resis-
tance causes changes in gene methylation. However, our multi- step 
approach in the validation sample of identifying a mediation effect 
reduces the chance of reverse causation. Finally, this work was per-
formed in the peripheral blood, which is heterogeneous in cell type. 
Our EWAS analysis used available strategies to control for the hetero-
geneity but we were unable to control for this in our validation sample, 
where the DNA had already been collected. Due to this heterogeneity, 
future work will need to translate the peripheral blood findings to a 
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target tissue. There are several target tissues that may be good can-
didates for investigating the epigenetic and molecular mechanisms of 
AAP- induced insulin resistance which our group is currently examining.
4  | CONCLUSIONS
This study identified and validated a differentially methylated CpG 
site in a novel gene associated with AAP- induced insulin resistance. 
We were able to identify a mediating effect of this CpG site on AAP- 
induced insulin resistance as well as possible functional effects of 
lipid metabolites. To date, we still do not fully understand the precise 
mechanism of AAP- induced insulin resistance. Identification of the 
mechanism of AAP- induced insulin resistance could lead to future per-
sonalized intervention strategies such as biomarkers that will allow us 
to screen patients for the risk of becoming insulin resistant or poten-
tially allow us to design drug therapy to prevent AAP- induced insulin 
resistance itself. The interventions based on such knowledge will allow 
clinicians to utilize AAPs for their beneficial, psychiatric effects, while 
minimizing or removing the detrimental effects on cardiometabolic and 
physical health which will ultimately improve a psychiatric patient’s 
morbidity and mortality. Going forward, targeted, prospective epige-
netic analyses in candidate insulin- sensitive tissues are needed to fully 
understand the interaction of genes and medications in the severely 
mentally ill.
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